(Q38210132)

31 August 2017

Ponatinib: a review of its use in adults with chronic myeloid leukaemia or Philadelphia chromosome-positive acute lymphoblastic leukaemia (English)

1 reference

31 August 2017

1 reference

ChEBI release 2020-05-28

1 reference

Sheridan M Hoy

1

1 reference

31 August 2017

1 May 2014

1 reference

31 August 2017

1 reference

31 August 2017

74

1 reference

31 August 2017

7

1 reference

31 August 2017

793-806

1 reference

https://scigraph.springernature.com/pub.10.1007/s40265-014-0216-6

31 August 2017

0 references

cites work

Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0216-6

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0216-6

Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0216-6

Ponatinib for chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0216-6

Ponatinib in refractory Philadelphia chromosome-positive leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0216-6

AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0216-6

Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0216-6

Effects of food on the pharmacokinetics of ponatinib in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0216-6

Effects of ketoconazole on the pharmacokinetics of ponatinib in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0216-6

A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0216-6

Current issues in chronic myeloid leukemia: monitoring, resistance, and functional cure

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24807266

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Clinical roundtable monograph: Emerging treatment options for TKI-resistant chronic myelogenous leukemia.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24807266

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S40265-014-0216-6

1 reference

PubMed ID

24807266

Dimensions Publication ID

31 August 2017

0 references

1 reference

PubMed ID

24807266